FDA Advisers Back a Melanoma Treatment for Patients Who Ran Out of Options, and a Decision Is Due Monday

FDA advisers voted 10-3 to back Replimune’s RP1 for advanced melanoma after two rejections. The agency’s decision is due August 2.

Have A Referral?